Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : NYU Langone Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX
Details : On the first day after surgery, patients receiving ORAVEXX (cannabidiol, CBD), experienced on average 23% less pain as measured by the Visual Analog Scale (VAS) pain score compared to patients receiving the placebo.
Brand Name : Oravexx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 25, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : NYU Langone Health
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?